30
Oct
2025
The Outsized Significance of A New Study of AI in Diabetes Prevention
A lifestyle intervention delivered by AI was found to be as effective as validated traditional interventions delivered by trained experts in a carefully conducted implementation study conducted by Johns Hopkins researchers and just published in JAMA. These results have broad significance and speak to the promise of AI to deliver promising behavior-change interventions at unprecedented scale. Context: The DPP The... Read More
28
Oct
2025
Innate Immune System Activators for Cancer: Art Krieg on The Long Run
Art Krieg is today’s guest on The Long Run. Art is the founder and CEO of a Cambridge, Mass.-based startup called Zola Therapeutics. Zola is developing an oligonucleotide drug candidate to activate a family of Toll-like receptors known as TLR7 TLR8 and TLR9. Activating these receptors is thought to spur the innate immune system to attack cancer cells. Art designed... Read More
27
Oct
2025
Report from China: Setting Sight on New Modalities and Global Markets
Chinese biotechs opened 2025 with a bang at JPM week, and the momentum has continued. Much of the conversation early this year was about how the US could rise to the challenge, and hold onto its historic position as the world leader in biotech innovation (see my Jan. 8, 2025 editorial in TR). The evidence of a China biotech renaissance... Read More
24
Oct
2025
The Biology of Belonging: Social Connection Meets Geroscience
Digital health, fitness, and longevity platforms have focused on the constant measurement and relentless optimization of biometric parameters, an often-valuable effort but one that has systematically left behind vital components of health and flourishing – such as social connection — that are more difficult to measure. The Health Value of Social Connection Robust longitudinal studies, including the Harvard Study of... Read More
23
Oct
2025
Takeda Bets on Innovent, NewLimit Lures Lilly, & Merck Makes in America
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2025
Novo Buys Akero, BMS Bets on Orbital In Vivo CAR-T, & a Biotech Industry Nobel
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2025
Creating a New Class of Medicines: Eric Fischer on The Long Run
Today’s guest on The Long Run is Eric Fischer. Eric is a professor at Dana Farber Cancer Institute in Boston. His structural biology and chemical biology expertise has led him down a path to become one of the world’s experts in an emerging category of medicine that includes targeted protein degraders and molecular glues. These novel chemical entities can be... Read More
13
Oct
2025
US Biotech Has an IRR Problem, Not a China Problem
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2025
Too Many Life Sciences Boards Are Shirking Responsibilities
There is a persistent myth in life sciences that once a company transitions from a scrappy startup into a more mature company, its board will naturally evolve to meet those new, more complex challenges. The reality is that these boards all too often fail to keep pace with their organizations. Those gaps leave management teams without the strategic guidance and... Read More
6
Oct
2025
Silicon Valley: Yes, AI Does Enhances Productivity — In The Right Hands & Context
Outside the glare of hyperbolic headlines, organizations of all sizes – including most in healthcare – are urgently trying to figure out how AI will fit into their workflows and business plans. Perhaps the most interesting recent discussion I’ve heard on this subject involved a trio of Andreessen-Horowitz (a16z) partners — Erik Torenberg, Martin Casado, and Steven Sinofsky — who were... Read More
6
Oct
2025
An Outstanding ‘Mini’ Traverse of Katahdin for Damon Runyon Cancer Research
The Timmerman Traverse for Damon Runyon Cancer Research Foundation had a spectacular experience on Mt. Katahdin in Maine on Saturday. Weather was glorious. Fall colors were vibrant. The team was fit and mentally ready for rocky, rugged terrain. They got a rich outdoor experience with a steep rock scramble on Cathedral Path, then crossing Katahdin’s famous Knife Edge ridge. This... Read More
6
Oct
2025
“Food Intelligence”: Make Healthy the Default — In Public Spaces and Private Kitchens
While “nutrition science” often seems to cry out for air quotes around “science,” we are fortunate now to have a new book on the topic written by one of the most thoughtful and deliberate nutrition researchers of the modern age: Kevin Hall. Hall has consistently steered a course of thoughtful rigor, leading a succession of highly impactful studies at the... Read More
6
Oct
2025
Arbor Takes Next-Gen Gene Editing into the Clinic, Secures Chiesi Partnership
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Oct
2025
Consumer Health’s Digital Convergence – And What’s Still Missing
Consumers are taking increased ownership of their health. As Laura Landro recently described in the Wall Street Journal, this trend is driven in part by necessity — specifically by “a shortage of doctors, long wait times for appointments and an increasing prevalence of chronic diseases such as diabetes earlier in adulthood.” But our push to manage our own health is also motivated... Read More
2
Oct
2025
Pfizer Buys Metsera GLP-1s, Genmab Nabs Merus for $8B, & Sanofi Commits to VC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2025
Cartography Secures $67M for T-cell Engager for Colorectal Cancer (and a Platform, Too)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Sep
2025
A Song of Science and Hope: Bruce Levine & Mags McCarthy on The Long Run
Today’s guests on The Long Run are Bruce Levine and Mags McCarthy. Bruce is a scientist at the University of Pennsylvania Perelman School of Medicine. He’s one of the world leaders in engineering CAR-T cell therapies for cancer. Mags McCarthy is a country music star. What do these two have in common? A shared desire to sing from the rooftops... Read More
18
Sep
2025
Roche Buys 89Bio, Novartis Doubles Down on Monte Rosa, & aTyr Flames Out
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Sep
2025
Predicting Leukemia Risk At Scale: Dr. Lachelle Weeks on The Long Run
Dr. Lachelle Weeks is today’s guest on The Long Run. Lachelle is a physician-scientist in the adult leukemia program at Dana-Farber Cancer Institute in Boston. She treats patients who have precursors to myeloid cancers such as acute myeloid leukemia. Her research is looking at ways to detect the early warning signs of blood cancer early, when these malignancies are most... Read More
17
Sep
2025
Arch-Backed Ollin Secures $100M For Bispecific Antibodies for Eye Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.